Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Cardiology > HFA 2021 > COVID-19 and the Heart > Myocardial infarction outcomes were significantly affected by the pandemic

Myocardial infarction outcomes were significantly affected by the pandemic

Presented by
Dr Ayman Haq, Baylor University Medical Center, USA
Conference
HFA 2021
    During the COVID-19 pandemic, patients with symptoms of a myocardial infarction waited longer before seeking medical attention. This resulted not only in delayed revascularisations but also in worse acute outcomes and rehospitalisation due to heart failure (HF) after 6 months.

    A retrospective, multicentre study with a cohort of patients from Lithuania aimed to assess whether the pandemic-provoked lockdowns affected the use of emergency healthcare in patients with ST-elevation myocardial infarction (STEMI) and non-STEMI [1]. Evaluated were COVID-19 negative patients treated for STEMI or non-STEMI between 11 March and 20 April 2020 and during the same period in 2019. “In total, we enrolled 269 individuals; 107 individuals or about 40% presented in 2020, during the pandemic, and 162 individuals or about 60% presented in 2019, prior to the pandemic. They were well matched in terms of gender and other comorbidities,” explained Dr Ayman Haq (Baylor University Medical Center, TX, USA). The study measured in-hospital outcomes and major adverse cardiovascular events (MACE), as well as the individual components of MACE at 6 months.

    “One of the most significant findings was how much longer patients were waiting to seek medical attention,” said Dr Haq. The overall pain-to-door time more than doubled from 385 minutes pre-pandemic to 858 minutes during the pandemic (P<0.0001). In the non-STEMI group, the difference was more pronounced with pain-to-door times of 558 and 2,021 minutes, respectively (P<0.0001). In the STEMI groups, the difference was also significant with pain-to-door times of 262 and 582 minutes, respectively (P=0.0003). Door-to-wire times were comparable for STEMI patients in 2019 and 2020, but numerically prolonged in 2020 for non-STEMI.

    Also, the overall initial troponin I values were worse in 2020, with 7.8 mg/L versus 4.5 mg/L before the pandemic. Furthermore, post-interventional left ventricular ejection fraction was decreased during the pandemic. Overall, the incidence of MACE at 6 months was greater in 2020 (30.8% vs 13.6%; P=0.0006). This difference was again more pronounced in the non-STEMI group. “On examining the individual components of MACE, we saw that there were no statistical significances in the rates of stroke, non-fatal myocardial infarction, cardiovascular death, or target vessel revascularisation at 6 months. However, rates of hospitalisation for decompensated heart failure had increased dramatically,” stated Dr Haq. Hospitalisation for decompensated heart failure was identified as a major driver of the rise in MACE events in 2020 by the researchers. For example, in patients with non-STEMI, a 20-fold increase of decompensated heart failure was observed during the pandemic (1.3% vs 30%; P<0.0001).

    Causality for these findings cannot be provided by the present study, but Dr Haq suggested that it is nonetheless important to emphasise that individuals should seek emergency medical attention during lockdowns and not delay or postpone care.


      1. Aldujeli A, et al. Association between delayed revascularization during the COVID-19 pandemic and rates of post myocardial infarction heart failure hospitalisations. Heart Failure and World Congress on Acute Heart Failure 2021, 29 June–1 July.

     

    Copyright ©2021 Medicom Medical Publishers



    Posted on